- Home
- NTZ vs IGC Comparison
NTZ vs IGC Comparison
Compare NTZ & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTZ | IGC |
|---|---|---|
| Founded | 1959 | 2005 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 31.2M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | NTZ | IGC |
|---|---|---|
| Price | $2.52 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 8.8K | ★ 933.9K |
| Earning Date | 01-01-0001 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $358,555,673.00 | $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.15 | $0.25 |
| 52 Week High | $5.50 | $0.50 |
Technical Indicators
Market Signals| Indicator | NTZ | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 39.57 |
| Support Level | $2.24 | $0.29 |
| Resistance Level | $2.69 | $0.36 |
| Average True Range (ATR) | 0.21 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 49.29 | 25.36 |
Price Performance
Historical ComparisonAbout NTZ Natuzzi S.p.A.
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.